Introduction
Radiotherapy is used in the management of roughly half of all solid tumours. Radiation also has the ability to activate promoters containing radio-responsive elements, and this has led to the development of therapeutic plasmids driven by radiation-inducible promoters. Radiation induction of the early growth response-1 (Egr-1) gene was first reported in 1991. 1 Furthermore, specific transcriptional control (CArG) elements were identified within the Egr-1 gene that are upregulated in response to ionizing radiation. 2 Treatment with the CArG/HSV-tk plasmid to activate the pro-drug ganciclovir in combination with radiation proved more effective than radiation or ganciclovir treatments alone. 3 This approach was further optimized by incorporating properties of the Cre/LoxP system. The CArG promoter in tandem with a basal cytomegalovirus (CMV) promoter was used to drive the expression of the Cre recombinase gene following a localized priming dose of radiation. The LoxP stop cassette of a second transfected plasmid is excised by the presence of Cre resulting in the expression of the transgene under control of the CMV promoter. Using this novel molecular switch, the numbers of transfected green fluorescent protein (GFP)-expressing cells increased 8.2-fold after a radiation trigger, compared to unirradiated control cells. There was a 40-fold induction of eGFP via the Cre/LoxP switch, compared to a three fold induction by the CArG promoter alone. 4, 5 Irradiation of oxygenated cells evokes damage by rapid generation of reactive oxygen species (ROS). 6 Mechanistic studies of the Egr-1 promoter have identified a role for the activation of the promoter in response to ROS. Induction by hydrogen peroxide (H 2 O 2 ) was shown to be quantitatively similar to that achievable by ionizing radiation. This was confirmed following treatment with N-acetyl-L-cysteine (a free-radical scavenger molecule), which resulted in a reduction of Egr-1 promoter activity. 2 Furthermore, the chemotherapeutic drug cisplatin induces its cytotoxic effects by generating ROS thereby activating the CArG promoter, which has been used to drive the expression of tumour necrosis factor (TNF)-a. 7 This approach resulted in significant tumour growth inhibition compared with either agent alone; although toxicity with cisplatin was observed, no additional toxicity was reported with the combination of cisplatin and TNF-a. 7 Inducible nitric oxide synthase (iNOS) gene therapy generates high levels of nitric oxide (NO K ) that can induce chemical damage to DNA resulting in apoptosis via the formation of reactive nitrogen oxide species, such as peroxynitrite (ONOO À ), which is generated when NO K reacts with superoxide (O 2 KÀ ). 8, 9 In a previous study we have shown that the CArG/iNOS construct may form a positive feedback loop, whereby the production of NO K , coupled with the elevated endogenous levels of NO K in tumours, resulted in the formation of ROS that in turn further activate the promoter. 10 Many tumours exhibit hypoxic regions reducing the effectiveness of radiotherapy. 6 Previously, we have shown that iNOS gene therapy diminished radioresistance observed under hypoxic conditions, thereby making it an ideal strategy for the treatment of solid tumours. 11 In the present study, the iNOS gene was cloned into a vector containing nine CArG element repeats (pE9/iNOS). Our previous physiological study of an ex vivo rat tail artery treated with pE9/iNOS showed rapid and more pronounced vasodilatation compared to CMV/iNOS-treated preparations, supporting our hypothesis of a positive feedback loop increasing the activation of the pE9 promoter. 10 Furthermore, significant antitumour effects were reported after a single 25 mg injection of the pE9/iNOS construct into intradermal radiation-induced fibrosarcoma (RIF)-1 tumours. A fourfold increase in protein expression and an eightfold increase in nitrite concentration within the tumour resulted in a 7-day delay in tumour growth as compared with untreated tumours. This was significantly more effective than in CMV/iNOS-treated tumours. 10 The present study aims to further evaluate the antitumour effects of the pE9/iNOS construct in combination with radiation. In addition, we aimed to demonstrate the radiosensitization by the overexpression of NO K within hypoxic tumour cells.
Results

iNOS protein expression following incremental radiation doses
Our previous studies demonstrated the ability of the pE9 promoter to drive high basal level iNOS transgene expression. In the present study, we designed the experiment to ascertain if increasing doses of ionizing radiation, within the clinically relevant range, led to higher levels of iNOS expression. RIF-1 murine sarcoma cells were transfected with the pE9/iNOS construct and assigned to one of three treatment groups receiving 0, 2 and 4 Gy doses. Samples were then collected 0, 0.5, 1, 2, 4, 8 and 24 h after irradiation, and probed for iNOS protein expression. Figure 1 illustrates relative iNOS protein expression over a 40 h period, corrected in relation to sample loading controls and determined by densitometry analysis. Radiation was given 16 h after transfection. Cells exposed to either 2 or 4 Gy X-rays demonstrated significantly elevated (P40.01 and 40.001 respectively) iNOS protein levels as compared with the non-irradiated cells. This translated into a mean 50% increase in iNOS protein over the duration of the time course, following a 4 Gy inducing radiation dose when compared to the non-irradiated cells.
Cytotoxicity of iNOS-expressing constructs in normoxic RIF-1 cells in vitro
RIF-1 cells were transfected under normoxic conditions with either a control pE9/GFP construct, or the CMV/iNOS or pE9/iNOS constructs, and treated with a radiation dose of 4 Gy, 16 h post transfection. A 4 Gy dose was selected as we previously demonstrated that approximately 50% of RIF-1 cells would survive this dose. 12 In addition, a non-irradiated pE9/iNOS-transfected control was included to highlight the combined toxicity that could be achieved following gene and radiotherapy. Cells transfected with the pE9/GFP construct acted as transfection controls, allowing corrections for transfection-associated toxicity, to which both the CMV/iNOS and pE9/iNOS plasmids were compared. Transfection with both iNOS-generating plasmids significantly (Po0.05) reduced clonogenic cell survival when compared with pE9/GFP-transfected cells receiving 4 Gy (Figure 2 ). This clearly demonstrates that the pE9/iNOS construct is capable of generating similar levels of cytotoxicity to the constitutively driven CMV/iNOS construct.
Cytotoxicity of iNOS expressing constructs in oxic RIF-1 cells in vitro
As we demonstrated in the normoxic clonogenic experiment and in our previous study, 10 the pE9 promoter generates iNOS expression and NO K -mediated toxicity comparable to that generated by CMV. Our next step was to establish whether the pE9/iNOS construct could radiosensitize hypoxic RIF-1 cells in vitro. Controls included an untreated normoxic RIF-1 group and Figure 1 Fold induction of inducible nitric oxide synthase (iNOS) protein expression following in response to incremental radiation doses. Transgene activation pre-irradiation was determined in our previous study, and used here to prevent unnecessary repetition. 10 Radiation-induced fibrosarcoma (RIF)-1 murine sarcoma cells were transfected with the pE9/iNOS construct; and samples were collected at seven time points post irradiation. Protein expression was then determined by western blot analysis. Data are based on densitometry analysis and are calculated after correction for the actin loading control. The graph represents the mean of three independent experiments ± s.e.m. (Figure 3a) . However, treatment with pE9/iNOS significantly (P40.0001) reduced clonogenic cell survival in an additive manner, suggestive of NO-mediated cytotoxicity rather than hypoxic cell radiosensitization. This effect was eliminated when the cells were treated with L-NMMA (Figure 3a) . When the oxygen concentration was reduced to 0.1%, there was substantial radio-resistance observed in hypoxic control cells across the range of radiation doses, with a significant difference (Po0.05) between the oxic and hypoxic at 9 Gy (Figure 3b ). Significant cytotoxicity of RIF-1 cells was observed following the treatment with the pE9/iNOS construct in the absence of radiation (Po0.05) reducing the increased clonogenicity conferred as a result of exposure to 0.1% oxygen (Figure 3b ). Furthermore, treatment of pE9/iNOS-transfected cells with L-NMMA significantly (Po0.001) reversed the NO K -induced radiosensitization.
As at the oxygen concentration of 0.1%, cells maintained at 0.01% oxygen exhibited significantly more resistance to increasing X-ray dose (Po0.05) than those under oxic conditions ( Figure 3c ). Transfection with pE9/ iNOS again caused direct cytotoxicity in the absence of radiation, but also clear evidence of radiosensitization was obtained. RIF-1 clonogenicity was reduced over the range of radiation doses, an effect which was completely reversible following the treatment with L-NMMA. In a further attempt to delineate between cytotoxicity 
or untreated, before being exposed to oxygen concentrations of (a) 1, (b) 0.1 or (c) 0.01%. Cells exposed to lower oxygen concentrations exhibited pronounced radio-resistance. This effect was greatly reduced following transfection with the pE9/iNOS construct. Furthermore, treatment with the NOS inhibitor blocked the radiosensitizing effects conferred by the pE9/iNOS construct. Data presented are the means of three independent experiments ± s.e.m.
Enhancement of pE9/iNOS gene therapy with radiation JA Coulter et al and NO K -induced radiosensitization we corrected the surviving fraction for each treatment condition in the absence of radiation to 1, eliminating NO K -induced cytotoxicity. Using nonlinear regression analysis and fitting basis functions of S.FBExp(Àa*DoseÀb*Dose^2) within confidence limits of 95%, we confirmed that an oxygen concentration of 1% was not sufficient to confer significant radio-resistance. In addition, there was no significant difference observed between the pE9/iNOStransfected cells and untreated cells irradiated in air, confirming that the observed differences were as a result of NO K -induced cytotoxicity. Using this model, we were also able to corroborate that the lower oxygen concentrations substantially increased radio-resistance, which was significantly reduced following transfection with the pE9/iNOS construct. As the oxygen tension decreased, an increase in clonogenicity was observed in RIF-1 cells in the absence of radiation (Figures 3a-c) ; possible explanations for this phenomena are discussed later.
Total nitrite (NO 2 À ) detection in oxic and chronic hypoxic conditions
In the absence of ionizing radiation, transfection of the pE9/iNOS construct resulted in a reduction of hypoxic RIF-1 cell clonogenicity. Tumour microenvironmental factors such as the stress evoked by a decrease in O 2 tension may result in increased expression of endogenous NO K , and as such result in pre-irradiation activation of the pE9 promoter. The Greiss test was used to determine the total nitrite (NO 2 À ) concentration in the medium of RIF-1 cells transfected with various iNOSproducing constructs under hypoxic and normoxic conditions (Figures 4a and b ). An oxygen concentration of 0.5% was selected to mimic the effects of chronic hypoxia; this was a compromise between 1% O 2 , where we observed a minimal difference in response to radiation, and 0.1% where long-term exposure over 96 h resulted in a dramatic reduction in the number of viable cells. Untreated control RIF-1 cells maintained under normoxia demonstrated no significant increase in NO 2 À concentration over a period of 96 h. However, there was a highly significant (Po0.001) increase in nitrite concentration in all cells transfected with either pE9/iNOS or CMV/iNOS after 48 h, with no significant increase between the 48 and 96 h time points (Figure 4a) . Cells maintained at an oxygen concentration of 0.5% exhibited a more gradual increase in the nitrite concentration. There was no significant difference between controls and either of the iNOS producing constructs. However, there were significant (Po0.01) increases in nitrite concentration for all treatment conditions between the time points (Figure 4b ).
Growth delay in RIF-1 tumours in vivo after iNOS gene therapy and/or irradiation Figure 5a shows the mean tumour volume measurements for all treatment groups taken every 2 days until the point of sacrifice. These curves were used to calculate the time taken for tumours in the different groups to reach a fourfold increase in volume from the day of first treatment. These times are shown in Figure 5b . The mean time taken for control tumours to increase fourfold in volume from 100 mm 3 was 7.17 days (±0.42 days). The efficacy of the pE9/iNOS gene therapy treatments was compared with vector-only-treated animals, resulting in a highly significant (Po0.001) reduction in the time taken for a fourfold increase in tumour volume. There was no significant difference between the effect of a 10 Gy radiation dose alone and treatment with CMV/ iNOS alone, taking 12.82 ( ± 0.79 days) and 12.64 days ( ± 0.95 days) respectively to reach 400 mm 3 . Both of these treatments were highly effective in the inhibition of tumour growth and were significantly different from controls (Po0.01 and o0.05 respectively). Tumours treated with the pE9/iNOS construct alone exhibited highly significant tumour growth delay compared to vector-only controls (Po0.001), as well as compared to radiation only (Po0.01) or CMV/iNOS-treated (Po0.01) tumours. When combined with radiation the effect of pE9/iNOS was even more dramatic, and tumours took a full week longer to reach the experimental end point of 400 mm 3 than after radiation only.
Discussion
Essential criteria for any potential gene therapy approach should include the incorporation of at least one level of demonstrated that specific regions within the promoter sequence of the Egr-1 gene were capable of inducing promoter activity in the presence of ionizing radiation. These transcriptional control elements were named CArG elements, which refer to short DNA motifs of 10 bp composed of CC(A/T)6GG. We have previously utilized the pE9 promoter, a synthetic promoter containing nine CArG repeats to drive iNOS transgene expression, and demonstrated in the absence of any inducing dose of radiation, iNOS protein expression comparable to that achieved following transfection with constitutively expressed CMV/iNOS. 10 Furthermore, we were able to demonstrate a positive feedback loop that allowed increased activation of the promoter by the generation of ROS in iNOS-expressing cells. In this follow-up study we aimed to assess the anticancer potential of the pE9/iNOS construct under oxidative stress and in combination with ionizing radiation.
Initially, the cytotoxic potential of the pE9/iNOS construct was determined following a 4 Gy radiation dose under normoxic conditions. Significant reductions in clonogenic cell survival (Po0.05) were observed in both cells treated with a 4 Gy radiation dose and the iNOS producing gene therapy constructs, as compared to vector-only-transfected cells. Inhibition studies investigating the role of ROS in the activation of the Egr-1 gene following ionizing radiation demonstrated that activity of the CArG promoter and subsequent Egr-1 expression were abrogated by the antioxidant scavenger N-acetyl-Lcystine. 2 This suggests that ROS generated by ionizing radiation are responsible for the activation of the CArG elements. Therefore, endogenous levels of NO K or low levels of iNOS transgene expression induced by tumour cell cytokines may be enough to initiate a positive feedback mechanism leading to further activation of the promoter. The significant reduction in clonogenic cell Enhancement of pE9/iNOS gene therapy with radiation JA Coulter et al survival under normoxic conditions strongly correlates with the increase in iNOS protein expression observed in Figure 1 . Although much of the toxic effects observed under normoxic conditions may be additive, the enhanced cytotoxicity underlines the potential of combinational therapies.
As tumour vasculature is generally poorly organized, solid tumours exhibit hypoxic regions, often centrally located, which are two-to threefold less sensitive to radiation than normoxic regions. To mimic the effects of hypoxia, and more specifically, the efficacy of iNOS overexpression resulting in increased hypoxic tumour sensitivity, RIF-1 cells were transfected with the pE9/ iNOS construct, exposed to a specific oxygen concentration and then treated with a range of radiation doses. There was no significant difference (P ¼ 0.95) in the cell survival curves between normoxic controls and untransfected RIF-1 cells maintained in 1% oxygen during irradiation (Figure 3b ). This suggests that 1% oxygen is sufficient to evoke the full oxygen enhancement ratio in these cells. This is consistent with the published data. 16 Furthermore, cells transfected with pE9/iNOS and treated with L-NMMA exhibited the highest level of cell survival after 9 Gy. As L-NMMA is a competitive inhibitor of all NOSs (that is, eNOS, iNOS and nNOS), promoter activation due to endogenous NO K is effectively eliminated, preventing the NO-mediated positive feedback mechanism and eliminating NO K -induced cytotoxicity.
Cells irradiated in 0.1 and 0.01% O 2 were significantly more resistant than those irradiated in air (P ¼ 0.0085 and 0.008 respectively), and the resistance was reversed by pE9/iNOS gene transfer. On closer examination the survival curves at the different O 2 concentrations suggest differences in response to the generation of NO K . The cytotoxic effect of NO K in 1% O 2 , in the absence of radiation, reduced cell survival to 66% of that in the absence of NO K (also under 1% O 2 ), but there was no evidence of a radiosensitizing effect, that is, a steepening of the cell survival curve. By contrast, the cytotoxic effect of NO K in 0.01% O 2 reduced survival by 111% compared to unirradiated control cells, exhibited by a significant (Po0.01) increase in the slope of the cell survival curve for CArG/iNOS-transfected cells compared to untransfected cells. This effect was entirely attributable to the decrease in the slope of the cell survival curve with decreasing O 2 concentration, and is consistent with the published oxygen enhancement ratios. 16 Thus, NO K generated as a consequence of iNOS gene transfer is able to substitute as a radiosensitizer at low oxygen tensions. A recent study has shown that at radiation doses in the range used in the present study, NO K is 10 times more potent than oxygen on a molar basis. 17 Perhaps, one of the most surprising effects seen in this study was the enhanced clonogenicity of RIF-1 cells exposed to 0.1 or 0.01% oxygen concentrations in the absence of any radiation dose. Furthermore, the effect of this increased clonogenicity was sustained in the presence of radiation up to 9 Gy. Several groups have demonstrated an induction in the activity of pro-survival pathways within cancer cells in response to hypoxia. 18, 19 Maxwell et al. 20 have recently highlighted a possible mechanistic explanation for the increased survival or clonogenicity of PC3 prostate cancer cells in a hypoxic environment. Exposure to hypoxia for as little as 1 h resulted in the elevated activity of hypoxia-inducible factor (HIF)-1 and nuclear factor (NF)-kB, which, in turn, led to a threefold induction in the levels of interleukin-8 (IL-8) and the IL-8 receptors CXCR1 and CXCR2. Treatment of normoxic PC3 cells with the chemotherapeutic agent etoposide resulted in a reduction of tumour cell viability by 20%. This effect was reduced to 8.5% under hypoxic conditions, highlighting the prosurvival actions of acute hypoxic. This is consistent with the present study in which cells were kept under hypoxia for 1.5 h. Inhibition of IL-8 signalling in the same hypoxic PC3 cells using small inhibitory RNA resulted in an enhanced sensitivity to 23% of that of normoxic maintained cells. Similarly, exposure of RIF-1 cells to acute hypoxia would most probably result in an upregulation of HIF-1 and NF-kB, activating prosurvival pathways and subsequently accounting for the elevated survival noted in the unirradiated hypoxic cells (Figures 3b and c) .
As the direct measurement of NO K production is impossible, the Greiss test was used to determine total NO 2 À concentration. This is an accurate measure of NO K production as NO K and its intermediates are eventually metabolized to NO 2 À and NO 3
À
. Untransfected control cells maintained at normoxic conditions exhibited no significant increase in total NO 2 À concentration over the 96 h time course. All cells transfected with iNOS generating constructs exhibited highly significant (Po0.001) increases in total NO 2 À concentration as compared to controls. This was not completely unexpected as we previously demonstrated activation of the pE9 promoter in the absence of radiation, and hypothesized that it may be in part due to a positive feedback loop, in which low levels of endogenous NO K cause promoter activation. 10 Untransfected control cells maintained at an oxygen concentration of 0.5% O 2 for 96 h exhibited significant (Po0.01) increases in NO 2 À concentration even though they were not transfected with iNOS-expressing plasmids or exposed to ionizing radiation ( Figure 4b ). As the duration and exposure to hypoxia increased, NO 2 À concentration increased accordingly in all groups suggesting that elevated endogenous NO K production occurred as a consequence of the hypoxic environment. Several other groups have demonstrated elevated levels of endogenous NO K in response to acute hypoxia, an effect that was greatly reduced in the presence of NOS inhibitors. 21, 22 As chronic hypoxia is a common feature of many solid tumours, and because of the self-inducing nature of the pE9/iNOS promoter in response to NO K , this gene therapy treatment may be augmented by the response to the tumour microenvironment.
The potential benefits of combined radio-and gene therapies were clearly demonstrated in our in vivo model. We have previously shown that the overexpression of the iNOS transgene results in significant in vivo tumour growth delay, both under the control of the WAF-1 and pE9 promoters. [10] [11] [12] Tumours treated with the pE9/ iNOS gene therapy construct took 3.68 days longer to reach the experimental end point, compared with tumours receiving 10 Gy alone. This highly significant (Po0.01) tumour growth delay clearly demonstrates the anticancer potential of iNOS gene therapy. Furthermore, similar tumour growth delay rates were observed as in our previous studies demonstrating the consistency Enhancement of pE9/iNOS gene therapy with radiation JA Coulter et al achievable with this gene therapy treatment. 10 The combination of pE9/iNOS with radiation delayed tumour growth by 7.93 days compared to 10 Gy of X-rays alone, and by 13.75 days when compared to untreated control animals. Despite the impressive additional tumour growth delay observed following the combination of both treatment modalities, a less than additive effect was observed. One possible explanation for this effect may relate to the target cell population. If the cytotoxicity produced by each therapy targeted a common sub-population of cells, the remaining viable population would eventually result in delayed tumour re-growth. Adenoviral iNOS gene therapy has also been used to enhance the effects of radiation in a rodent tumour model. 23 In that study, radiopotentiation between 1.34-and 1.93-fold in terms of growth delay was achieved depending on the p53 status of the tumour cell line. In the present study, growth delay in our RIF-1 (p53 +/+ ) model was increased 1.63-fold by the addition of gene therapy to the radiation therapy.
A significant concern with therapies promoting overexpression of NO K is systemic toxicity, specifically relating to systemic hypotension due to the vasodilator properties of NO K . In our own previous studies, [10] [11] [12] 15, 24 and those of others, 23, 25, 26 delivery of the iNOS transgene was used as a means of targeting NO K generation to the specific target site. We have shown that the pE9/iNOS system in combination with radiation caused a significant reduction in clonogenic cell survival in vitro and in vivo. All the animals treated with pE9/iNOS tolerated treatment well with no obvious adverse effects. Despite this the 'leaky' nature of the pE9 promoter is a cause for concern, particularly if the treatment was to be considered for systemic administration. Incorporation of the Cre/LoxP molecular switch to add an extra level of specificity has been extensively utilized in other molecular gene therapy strategies, and as such may prove an extremely useful tool for harnessing the potential of the pE9 promoter for driving iNOS expression. [27] [28] [29] [30] In summary, we have highlighted the potential of combining the pE9/iNOS gene therapy treatment with conventional treatments to enhance therapeutic outcomes. While demonstrating radio-resistance conferred by tumour cell hypoxia, we showed that transfection of hypoxic cells with iNOS-expressing constructs could cause substantial radiosensitization. This is particularly important as chemo-and radio-resistance caused by tumour hypoxia significantly limit the efficacy of current treatment programmes.
Materials and methods
Vector constructs
The CMV/iNOS and pE9/iNOS constructs were cloned as previously described. 3, 10, 12 The pE9/GFP construct again was cloned as previously described and was used as vector control in all experiments. 5 
Maintenance of cells in vitro
All cell culture reagents were obtained from Invitrogen (Paisley, UK) unless stated otherwise. The anticancer potential of the CMV/iNOS and pE9/iNOS plasmids was evaluated in RIF-1 murine sarcoma cells, which were a kind gift from Professor Martin Brown, Stanford University, CA, USA. These cells were used for both in vitro and in vivo experiments to maintain consistency between experiments. RIF-1 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. Cells were grown in monolayers in tissue culture flasks at 37 1C under 5%CO 2 /95% air and subcultured in every 3-4 days to maintain exponential growth.
In vitro transfections
RIF-1 cells were transfected with pEGFP-N1 using lipofectamine with plus reagent according to the manufacturer's instructions to ascertain the optimal transfection efficiency. Five fields of view were counted per transfected 35 mm dish, and three independent experiments were performed. Twenty-four hours post transfection, the ratio of fluorescent GFP-expressing cells to non-transfected cells was calculated. 
Radiation clonogenic assay
A total of 2 Â 10 6 cells were plated into T25 tissue culture flasks and incubated in complete RPMI 1640 medium at 37 1C overnight. Cells were transfected with one of the following constructs pE9/GFP (vector only), CMV/iNOS or pE9/iNOS. Twenty-four hours later the cells were plated into six-well plates. Cells were seeded at 200 and 500 cells per well. Non-transfected control cells were also plated under identical conditions compared to transfected cells. Cells transfected with the iNOS-containing plasmids were plated both in the presence and absence of BH 4 , a cofactor necessary for the production of NO K from iNOS. To assess radiation inducibility of the constructs, all conditions were plated in the presence and absence of a 4 Gy priming dose of radiation. Plates were incubated for 14 days at 37 1C in 5% CO 2 /95% air, and then colonies were fixed and stained with 0.4% crystal violet in 70% methanol and counted. Three independent experiments were carried out and the results were reported as mean ± s.e.. One-way ANOVA was used to determine statistical significance.
Hypoxic exposures
Clonogenic assays also were performed under various degrees of hypoxia. This was achieved by exposing cells in six-well plates to varying O 2 concentrations (1, 0.1 and 0.001%) in an Invivo 2 400 (Ruskinn technology, Mid Glamorgan) hypoxia workstation for 1.5 h and then sealing the plates with parafilm before immediately administering the appropriate dose of radiation (0, 3, 6 and 9 Gy). Plates were incubated for 14 days at 37 1C in 5% CO 2 /95% air, and then colonies were fixed and stained with 0.4% Crystal Violet in 70% methanol and counted. Three independent experiments were carried out and the results were reported as mean±s.e. One-way ANOVA was used to establish statistical significance. To allow delineation between the cytotoxic and radiosensitization effects of NO K , the surviving fraction for each treatment condition, in the absence of radiation, was corrected to 1, eliminating NO K -induced cytotoxicity. Nonlinear regression analysis with 95% confidence intervals was performed to determine significance.
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Irradiation procedures
In vitro. Under normoxic conditions, cells were directly irradiated in T25 flasks 16 h post transfection. Hypoxic cell clonogenics were plated and exposed to the appropriate O 2 before immediately sealing the six-well plates and administering the appropriate radiation dose. All radiation doses were given using a Faxitron 160 kVp X-ray machine (Qados Ltd, Berkshire).
In vivo. In vivo animals receiving a radiation dose were restrained unanaesthetized in a specifically designed lead jig, which protects the body of the animal while exposing the tumour on the rear dorsum. The radiation dose was delivered as two parallel-opposed fields using a Faxitron 160 kVp X-ray generator.
Total nitrite (NO 2 À ) detection in oxic and hypoxic conditions
The three step Greiss test (Active Motif Inc., Rixensart, Belgium) converts nitrate (NO 3 À ) to NO 2 À giving a total NO 2 À concentration, which can be quantified by constructing a NO 2 À standard curve. Hypoxia-treated cells were maintained under hypoxic conditions in an In vivo hypoxia workstation at an oxygen concentration of 0.5% for 96 h. Media samples were taken at three time points (0, 48 and 96 h) from RIF-1 cultures. RPMI 1640 cell culture medium could not be used in this test as it is unsuitable for the Greiss test analysis because of intrinsically high levels of NO 2 À /NO 3 À . This problem was overcome by plating out in RPMI 1640, transfecting and replacing the medium with minimum essential medium (MEM) for the duration of the experiment. Three independent experiments were carried out and the results were reported as mean ± s.e. One-way ANOVA was used to determine statistical significance.
Determination of RIF-1 tumour growth delay
Tumours for in vivo experiments were obtained by intradermal injection of 2 Â 10 5 RIF-1 cells (in a total volume of 0.1 ml of PBS) on the rear dorsum of lightly anaesthetized (isofluorane inhalation) 10-to 12-week-old female C3H mice. Mice were treated when the tumour volume reached B100 mm 3 measured by callipers in three dimensions. When tumours reached the treatment size of B100 mm 3 they were assigned to specific treatment groups, that is, untreated controls, vector only (pE9/GFP), radiation only (10 Gy), CMV/iNOS only, pE9/iNOS only, CMV/iNOS plus 10 Gy and pE9/iNOS plus 10 Gy. Animals receiving gene therapy treatments were injected intratumourally with 25 mg of the appropriate construct combined with 25 ml of lipofectamine 2000 and 50 ml of optiMEM-1. All animals treated with the iNOS-expressing constructs were given 200 ml of 10 À3 M BH 4 by intraperitoneal injection, 24 h post gene therapy treatment, followed by a 10 Gy radiation dose for the appropriate treatment groups. Tumours were measured with callipers in three dimensions every 2 days. The geometric mean was calculated and used to determine tumour volume. Efficacy of gene therapy treatments was assessed by the time taken for tumours to reach four times their volume from the commencement of treatment. All animal experiments were carried out in accordance with the Animal (Scientific Procedures) Act 1986 and conformed to the current UKCCCR guidelines.
One-way ANOVA was used to determine significance of differences between groups.
